NCT04119440View on ClinicalTrials.gov

Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS

PHASE1CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

April 16, 2021

Primary Completion Date

November 28, 2022

Study Completion Date

November 6, 2024

Conditions
MERS (Middle East Respiratory Syndrome)
Interventions
BIOLOGICAL

MVA-MERS-S_DF1 - Low Dose

Administrations of the low dose via the intramuscular route

BIOLOGICAL

MVA-MERS-S_DF1 - High Dose

Administrations of the high dose via the intramuscular route

OTHER

Placebo

Administrations of placebo via the intramuscular route

Trial Locations (2)

3015

Erasmus Medical Centre, Rotterdam

20246

University Medical Center Hamburg-Eppendorf, Hamburg

Sponsors
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

IDT Biologika Dessau.Rossau

UNKNOWN

collaborator

German Center for Infection Research

OTHER

collaborator

CR2O

UNKNOWN

collaborator

Erasmus Medical Center

OTHER

collaborator

Monipol Deutschland GmbH

UNKNOWN

lead

Universitätsklinikum Hamburg-Eppendorf

OTHER